Study of a new radiotracer for cancer imaging
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study in Patients With Various Cancers
This study is testing a new imaging agent for cancer to see how well it helps doctors spot tumors in patients with different types of cancer.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 5 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06688188 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety, biodistribution, and radiation dosimetry of a novel radiotracer, 68Ga-JH12, which targets the C-X-C motif chemokine receptor 4 (CXCR4) in patients with various types of cancer. The research aims to determine how well this radiopharmaceutical accumulates in tumors and its potential effectiveness in imaging malignant neoplasms. By analyzing the dosimetric characteristics of 68Ga-JH12, the study seeks to enhance cancer diagnosis and treatment planning. Participants will undergo PET/CT scans to assess the radiotracer's performance in real-time.
Who should consider this trial
Good fit: Ideal candidates include patients with various solid tumors who have confirmed histopathological findings.
Not a fit: Patients who are pregnant, lactating, or have severe hepatic and renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve cancer imaging techniques, leading to better diagnosis and treatment strategies for patients with malignant tumors.
How similar studies have performed: Other studies have shown success with similar approaches targeting CXCR4 in cancer imaging, indicating a promising avenue for further exploration.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Various solid tumors with available histopathological findings * Signed informed consent Exclusion Criteria: * pregnant or lactational women * who suffered from severe hepatic and renal insufficiency
Where this trial is running
Fuzhou, Fujian
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: +86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.